Patents by Inventor John R. Stephenson

John R. Stephenson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9926342
    Abstract: The present invention provides a recombinant protein comprising consecutive amino acids, the sequence of which is substantially identical to a sequence of amino acids present in a Rhodococcus equi virulence-associated protein and compositions containing fusion proteins of the invention. The present invention also provides uses of the compositions in the manufacture of hyperimmune plasma against Rhodococcus equi, in producing a hyperimmune plasma against Rhodococcus equi in protecting an animal against Rhodococcus equi and in protecting a newborn animal against Rhodococcus equi.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 27, 2018
    Assignee: SANTA CRUZ BIOTECHNOLOGY, INC.
    Inventor: John R. Stephenson
  • Publication number: 20150023983
    Abstract: The present invention provides a recombinant protein comprising consecutive amino acids, the sequence of which is substantially identical to a sequence of amino acids present in a Rhodococcus equi virulence-associated protein and compositions containing fusion proteins of the invention. The present invention also provides uses of the compositions in the manufacture of hyperimmune plasma against Rhodococcus equi, in producing a hyperimmune plasma against Rhodococcus equi in protecting an animal against Rhodococcus equi and in protecting a newborn animal against Rhodococcus equi.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 22, 2015
    Applicant: SANTA CRUZ BIOTECHNOLOGY, INC.
    Inventor: John R. Stephenson
  • Publication number: 20030166281
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.
    Type: Application
    Filed: April 16, 2002
    Publication date: September 4, 2003
    Applicant: OSI Pharmaceuticals, Inc.
    Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson, Robert Franco
  • Publication number: 20030138773
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene of interest, the expression of which is associated with a defined physiological or pathological effect within a multicellular organism. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) specifically transcriptionally modulate expression of the gene of interest, and (c) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell, the binding of a ligand to which ligand binding domain is normally associated with the defined physiological or pathological effect.
    Type: Application
    Filed: March 25, 1998
    Publication date: July 24, 2003
    Inventors: J. GORDON FOULKES, ROBERT FRANCO, FRANZ LEITCHTFRIED, CHRISTIAN PIELER, JOHN R. STEPHENSON
  • Patent number: 6589733
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene of interest, the expression of which is associated with a defined physiological or pathological effect within a multicellular organism. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) specifically transcriptionally modulate expression of the gene of interest, and (c) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell, the binding of a ligand to which ligand binding domain is normally associated with the defined physiological or pathological effect.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 8, 2003
    Assignee: Osi Pharmaceuticals, Inc.
    Inventors: J. Gordon Foulkes, Robert Franco, Franz Leichtfried, Christian Pieler, John R. Stephenson
  • Patent number: 6586394
    Abstract: This invention is directed to a chromatographically recovered polypeptide having the N-terminal amino acid sequence Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Clu-Asn-Cys-Cys-Val. This polypeptide is known as TGI, TGI-1 and TGI-2. It is also referred to as TGF-&bgr;3. The invention is also directed to a compositions which comprises the chromatographically recovered polypeptide. The invention also provides a pharmaceutical compositions to inhibit the growth of epithelial cells or heal a wound or treat a burn consisting of the chromatographically recovered polypeptide. The invention is also directed to methods which comprise administering to a subject an effective amount of the chromatographically recovered so as to thereby inhibit the growth of epithelial cells, or heal the wound or treat the burn.
    Type: Grant
    Filed: January 27, 1994
    Date of Patent: July 1, 2003
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Kenneth K. Iwata, John R. Stephenson, Leslie I. Gold
  • Patent number: 6559123
    Abstract: This invention is directed to a method of treating a burn or healing a wound in a mammal by administering a chromatographically recovered polypeptide having the N-terminal amino acid sequence Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val. This polypeptide is known as TGI, TGI-1 and TGI-2. It is also referred to as TGF-&bgr;3. The invention is also directed to a compositions which comprises the chromatographically recovered polypeptide. The invention also provides a pharmaceutical compositions to inhibit the growth of epithelial cells or heal a wound or treat a burn consisting of the chromatographically recovered polypeptide.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: May 6, 2003
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Kenneth K. Iwata, John R. Stephenson, Leslie I. Gold
  • Patent number: 6425769
    Abstract: The invention provides a recombinant nucleic acid vector comprising a nucleic acid encoding a polypeptide of 112 amino acids having the amino acid sequence shown in FIG. 29 beginning with alanine at position 1 and ending with serine at position 112. The sequence of FIG. 29 represents a member of the TGF-&bgr; family of tumor growth factors. The invention also provides a method for producing a protein which comprises culturing the host cell under conditions suitable to express the protein in the host cell and recovering the protein so produced.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: July 30, 2002
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Kenneth K. Iwata, John R. Stephenson, Peter ten Dijke
  • Patent number: 6376175
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.
    Type: Grant
    Filed: July 28, 1998
    Date of Patent: April 23, 2002
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson, Robert Franco
  • Patent number: 6203976
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene encoding a protein of interest, the expression of which gene is associated with the production in cell culture of a protein encoded by the gene, which comprises contacting a cell, which is capable of expressing the gene, with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell in culture, which molecule (a) does not naturally occur in the cell and (b) directly transcriptionally modulates expression of the gene.
    Type: Grant
    Filed: June 7, 1994
    Date of Patent: March 20, 2001
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: J. Gordon Foulkes, Franz E. Leichtfried, Christian Pieler, John R. Stephenson
  • Patent number: 6165712
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene encoding a protein of interest, the expression of which gene is associated with the production in cell culture of a protein encoded by the gene, which comprises contacting a cell, which is capable of expressing the gene, with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell in culture, which molecule (a) directly transcriptionally modulates expression of the gene.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 26, 2000
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: J. Gordon Foulkes, Franz E. Leichtfried, Christian Pieler, John R. Stephenson, Casey C. Case
  • Patent number: 6136779
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.
    Type: Grant
    Filed: January 6, 1997
    Date of Patent: October 24, 2000
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson
  • Patent number: 6083709
    Abstract: The invention provides a method for diagnosing in a subject a neoplastic condition which comprises (a) obtaining from the subject a sample of a biological fluid; and (b) detecting the presence in the sample of a mutant p53 polypeptide encoded by an activated p53 oncogene, the presence of the mutant p53 polypeptide in the sample indicating that the subject has the neoplastic condition.
    Type: Grant
    Filed: November 23, 1993
    Date of Patent: July 4, 2000
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Frederick H. Reynolds, Jr., Ron Zeheb, John R. Stephenson, John M. Sorvillo
  • Patent number: 5976793
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.
    Type: Grant
    Filed: July 18, 1996
    Date of Patent: November 2, 1999
    Assignee: Oncogene Science, Inc.
    Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson
  • Patent number: 5863733
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.
    Type: Grant
    Filed: January 6, 1997
    Date of Patent: January 26, 1999
    Assignee: Oncogene Science, Inc.
    Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson
  • Patent number: 5846720
    Abstract: The invention provided for a method of transcriptionally modulating the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease. Further provided is a method of determining whether a molecule not previously known to be a modulator of protein biosynthesis is capable of directly and specifically transcriptionally modulating the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease. Screening methods, including methods of essentially simultaneously screening molecules to determine whether the molecules are capable of directly and specifically transcriptionally modulating one or more genes encoding proteins of interest associated with treatment of one or more symptoms of a cardiovascular disease, are also provided.
    Type: Grant
    Filed: August 15, 1996
    Date of Patent: December 8, 1998
    Assignee: Oncogene Science, Inc.
    Inventors: J. Gordon Foulkes, Franz E. Liechtfried, Christian Pieler, John R. Stephenson, Casey C. Case
  • Patent number: 5776502
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene of interest, the expression of which is associated with a defined physiological or pathological effect within a multicellular organism. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) specifically transcriptionally modulate expression of the gene of interest, and (c) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell, the binding of a ligand to which ligand binding domain is normally associated with the defined physiological or pathological effect.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 7, 1998
    Assignee: Oncogene Science, Inc.
    Inventors: J. Gordon Foulkes, Robert Franco, Franz Leichtfried, Christian Pieler, John R. Stephenson
  • Patent number: 5665543
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.
    Type: Grant
    Filed: June 28, 1994
    Date of Patent: September 9, 1997
    Assignee: Oncogene Science, Inc.
    Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson, Robert Franco
  • Patent number: 5580722
    Abstract: The invention provided for a method of directly and specifically transcriptionally modulating the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease such as atherosclerosis, restenosis or hypertension.Further provided is a method of determining whether a molecule not previously known to be a modulator of protein biosynthesis is capable of directly and specifically transcriptionally modulating the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease.Lastly, the invention provides a method of directly and specifically transcriptionally modulating in a human being the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease, thus ameliorating the disease.
    Type: Grant
    Filed: February 7, 1992
    Date of Patent: December 3, 1996
    Assignee: Oncogene Science, Inc.
    Inventors: J. Gordon Foulkes, Franz E. Liechtfried, Christian Pieler, John R. Stephenson, Casey C. Case
  • Patent number: 4681840
    Abstract: A single-stranded deoxyribonucleic acid molecule having a length of less than about 25 kb comprises at least three distinct nucleotide sequences which are the sites for incorporation into a chromosome of a deoxyribonucleic acid molecule encoding a deleterious gene. Deoxyribonucleic acid probes have been prepared from such molecules and are useful as hybridization probes for detecting chromosomal deoxyribonucleic acid which has a deoxyribonucleic acid molecule encoding a deleterious gene, i.e. oncogene, incorporated therein.A single-stranded deoxyribonucleic acid molecule derived from human chromosome 22 which is about 5.8 kb in length contains sites for incorporation of a deoxyribonucleic acid molecule encoding the oncogene c-abl derived from human chromosome 9. Deoxyribonucleic acid probes have been prepared from this molecule and used to detect the abnormal Philadelphia chromosome and chronic myelocytic leukemia.
    Type: Grant
    Filed: January 18, 1984
    Date of Patent: July 21, 1987
    Assignee: The United States of America as represented by the Secretary of Commerce
    Inventors: John R. Stephenson, John Groffen, Nora Heisterkamp